Top

Published in:

03-11-2023 | Lichen Planus | Review

Systemic non-steroidal immunomodulators for oral lichen planus treatment—a scoping review

Authors: Erick Souza Pedraça, Eduardo Liberato da Silva, Taiane Berguemaier de Lima, Pantelis Varvaki Rados, Fernanda Visioli

Published in: Clinical Oral Investigations | Issue 12/2023

Abstract

Objective

The aim of this scoping review was to evaluate the efficacy and safety of the use of systemic nonsteroidal immunomodulators (SNSI) for oral lichen planus (OLP) treatment.

Materials and methods

This review was conducted according to PRISMA-ScR guidelines and registered at PROSPERO (CRD42021243524). Consulted databases were Pubmed, Embase, Scopus, and Web of Science. The inclusion criteria was as follows: clinical trials, case series, prospective, and retrospective studies conducted with participants presenting OLP of any sex and age.

Results

Thirty-two studies were selected, assessing 9 different SNSI: methotrexate, dapsone, levamisole, hydroxychloroquine, thalidomide, metronidazole, azathioprine, mycophenolate mofetil, and colchicine. Methotrexate and dapsone were the drugs with the best evidence among the options included, regarding number and quality of studies. Methotrexate resulted in significant improvement in the clinical condition and remission of symptoms, ranging between 63 and 93% of cases. Dapsone presented a similar effect to the use of topical corticosteroids and tacrolimus

Conclusion

Among SNSI therapeutic options, methotrexate, and dapsone showed promising efficacy and safety. However, large-scale randomized clinical trials are still needed.

Clinical relevance

SNSI have been used in the treatment of recalcitrant OLP; however, so far, it is not clear which are the best options. This scoping review highlights the potential use of methotrexate and dapsone.

Available only for authorised users

Scully C, Carrozzo M (2008) Oral mucosal disease: lichen planus. Br J Oral Maxillofac Surg 46(1):15–21. https://doi.org/10.1016/j.bjoms.2007.07.199CrossRefPubMed

Farhi D, Dupin N (2010) Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol 28(1):100–108. https://doi.org/10.1016/j.clindermatol.2009.03.004CrossRefPubMed

Payeras MR, Cherubini K, Figueiredo MA, Salum FG (2013) Oral lichen planus: focus on etiopathogenesis. Arch Oral Biol 58(9):1057–1069. https://doi.org/10.1016/j.archoralbio.2013.04.004CrossRefPubMed

González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, González-Ruiz L, Ayén Á, Lenouvel D, Ruiz-Ávila I, Ramos-García P (2021) Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis. Oral Dis 27(4):813–828. https://doi.org/10.1111/odi.13323CrossRefPubMed

Zakrzewska JM, Chan ES, Thornhill MH (2005) A systematic review of placebo-controlled randomized clinical trials of treatments used in oral lichen planus. Br J Dermatol 153(2):336–341. https://doi.org/10.1111/j.1365-2133.2005.06493.xCrossRefPubMed

Gangeshetty N, Kumar BP (2015) Oral lichen planus: etiology, pathogenesis, diagnosis, and management. World J Stomatol 4(1):12–21. https://doi.org/10.5321/wjs.v4.i1.12CrossRef

Olson MA, Rogers RS 3rd, Bruce AJ (2016) Oral lichen planus. Clin Dermatol 34(4):495–504. https://doi.org/10.1016/j.clindermatol.2016.02.023CrossRefPubMed

Ismail SB, Kumar SK, Zain RB (2007) Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci 49(2):89–106. https://doi.org/10.2334/josnusd.49.89CrossRefPubMed

Crincoli V, Di Bisceglie MB, Scivetti M, Lucchese A, Tecco S, Festa F (2011) Oral lichen planus: update on etiopathogenesis, diagnosis and treatment. Immunopharmacol Immunotoxicol 33(1):11–20. https://doi.org/10.3109/08923973.2010.498014CrossRefPubMed

10.

Alrashdan MS, Cirillo N, McCullough M (2016) Oral lichen planus: a literature review and update. Arch Dermatol Res 308(8):539–551. https://doi.org/10.1007/s00403-016-1667-2CrossRefPubMed

11.

Suresh SS, Chokshi K, Desai S, Malu R, Chokshi A (2016) Medical management of oral lichen planus: a systematic review. J Clin Diagn Res 10(2):ZE10-5. https://doi.org/10.7860/JCDR/2016/16715.7225CrossRefPubMed

12.

da Silva EL, de Lima TB, Rados PV, Visioli F (2021) Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. Clin Oral Investig 25(9):5149–5169. https://doi.org/10.1007/s00784-021-04072-7CrossRefPubMed

13.

Gujjar P, Zingade J, Patil S, Hallur J (2015) Recent update on treatment modalities of oral lichen planus-a review. IJSS Case Reports & Reviews 2(4):40–44 https://imsear.searo.who.int/handle/123456789/169144

14.

Chauhan P, De D, Handa S, Narang T, Saikia UN (2018) A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus. Dermatol Ther 31(1). https://doi.org/10.1111/dth.12563

15.

Alsakaan NAG, Abd-Elsalam S, Fawzy MM, Elwan NM (2022 Nov) Efficacy and safety of oral methotrexate versus oral mini pulse betamethasone therapy in the treatment of lichen planus: a comparative study. J Dermatolog Treat 33(7):3039–3046. https://doi.org/10.1080/09546634.2022.2104446CrossRef

16.

Meeri H, Niina H, Jaana W (2019) Systemic medication of patients with oral lichen planus in Turku University Hospital. J Oral Pathol Med 48:49–50. https://doi.org/10.1111/jop.12796CrossRef

17.

Ilyas S, Inayat S, Khurshid K, Asad F, Rani Z, Pal SS (2016) Efficacy and safety of methotrexate in lichen planus. J Pak Assoc Dermatol 26(1):41–47 https://www.jpad.com.pk/index.php/jpad/article/view/73/55

18.

Lajevardi V, Ghodsi SZ, Hallaji Z, Shafiei Z, Aghazadeh N, Akbari Z (2016) Treatment of erosive oral lichen planus with methotrexate. J Dtsch Dermatol Ges 14(3):286–293. https://doi.org/10.1111/ddg.12636CrossRefPubMed

19.

Steele JC, Li VCY, Rajlawat BP, Field EAL, Yesudian PD (2014) Methotrexate-responsive oral lichen planus: an analysis of 28 patients. Br J Dermatol 171:26–26. https://doi.org/10.1111/bjd.12931CrossRef

20.

Shah SA, Shah SF, Wahid A, Bangash ZQ, Bangash H (2014) Oral lichen planus: different trends in treatment. J Med Sci 22(3):137–142 https://www.jmedsci.com/index.php/Jmedsci/article/view/266

21.

Malekzad F, Saeedi M, Ayatollahi A (2012) Low dose methotrexate for the treatment of generalized lichen planus. http://www.iranjd.ir/article_98160.html. Acessed 08/03/2022

22.

Yesudian PD, Rajlawat BP, Field AE (2009) Effectiveness of methotrexate in oral lichen planus: experience in a specialist oral medicine/dermatology clinic. Br J Dermatol 161:13–13. https://doi.org/10.1111/j.1365-2133.2009.09125.xCrossRef

23.

Torti DC, Jorizzo JL, McCarty MA (2007) Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol 143(4):511–515. https://doi.org/10.1001/archderm.143.4.511CrossRefPubMed

24.

Saeed T, Firdous S, Malik SI, Aamir M, Ishaq Y, Riaz N (2021) Comparison of low dose oral methotrexate vs systemic corticosteroids for treatment of oral lichen planus. Pak J Med Health Sci 15(5):898–901. https://doi.org/10.53350/pjmhs21155898CrossRef

25.

Singh AR, Rai A, Aftab M, Jain S, Singh M (2017) Efficacy of steroidal vs non-steroidal agents in oral lichen planus: a randomized, open-label study. J Laryngol Otol 131(1):69–76. https://doi.org/10.1017/S0022215116009658CrossRefPubMed

26.

Agarwal S, Gupta G, Sayal SK (2013) Comparative study of the therapeutic efficacy of the dapsone (alone), dapsone plus tacrolimus (topical) and dapsone plus triamcinolone (topical) in oral lichen planus. Indian J Public Health Res Develop 4(1):83–86

27.

Raj AK, Sreelatha KT, Balan A, Kailasam S (2012) Dapsone in the treatment of resistant oral erosive lichen planus: a clinical study. J Indian Acad Oral Med and Radiol 24:20–23. https://doi.org/10.5005/JP-JOURNALS-10011-1253CrossRef

28.

Kumar B, Kaur I, Sharma VK (1989) Efficacy of dapsone in lichen planus. Indian J Dermatol Venereol Leprol 55(3):164–166 https://pubmed.ncbi.nlm.nih.gov/28128157/PubMed

29.

Lu SY, Chang TF, Lin CJ (2019) Treatment effectiveness of levamisole plus prednisolone on oral lichen planus patients with emphasis on levamisole-induced agranulocytosis or pancytopenia. J Formos Med Assoc 118(8):1193–1201. https://doi.org/10.1016/j.jfma.2019.03.007CrossRefPubMed

30.

Won TH, Park SY, Kim BS, Seo PS, Park SD (2009) Levamisole monotherapy for oral lichen planus. Ann Dermatol 21(3):250–254. https://doi.org/10.5021/ad.2009.21.3.250CrossRefPubMedPubMedCentral

31.

Lu SY, Chen WJ, Eng HL (1998) Response to levamisole and low-dose prednisolone in 41 patients with chronic oral ulcers: a 3-year open clinical trial and follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86(4):438–445. https://doi.org/10.1016/s1079-2104(98)90370-5CrossRefPubMed

32.

Lu SY, Chen WJ, Eng HL (1995) Dramatic response to levamisole and low-dose prednisolone in 23 patients with oral lichen planus: a 6-year prospective follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 80(6):705–709. https://doi.org/10.1016/s1079-2104(05)80255-0CrossRefPubMed

33.

Lin HP, Wang YP, Chia JS, Chiang CP, Sun A (2011) Modulation of serum gastric parietal cell antibody level by levamisole and vitamin B12 in oral lichen planus. Oral Dis 17(1):95–101. https://doi.org/10.1111/j.1601-0825.2010.01711.xCrossRefPubMed

34.

Sun A, Chiang CP (2001) Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus. J Oral Pathol Med 30(9):542–548. https://doi.org/10.1034/j.1600-0714.2001.300906.xCrossRefPubMed

35.

Yeshurun A, Bergman R, Bathish N, Khamaysi Z (2019) Hydroxychloroquine sulphate therapy of erosive oral lichen planus. Australas J Dermatol 60(2):e109–e112. https://doi.org/10.1111/ajd.12948CrossRefPubMed

36.

McParland H, Momen SE, Ormond M, Shirlaw PJ, Setterfield JF (2016) Efficacy of hydroxychloroquine in 43 patients with oral lichen planus. Oral Dis 22:14–14. https://doi.org/10.1111/odi.12559CrossRef

37.

Sondhi M, Mehta KS, Mahajan V, Chauhan PS, Minhas A, Dhattarwal N, Rana A (2020) Safety and efficacy of hydroxychloroquine in patients of symptomatic oral lichen planus. J Pak Assoc Dermatol 30(3):468–473 https://www.jpad.com.pk/index.php/jpad/article/view/1477/1431

38.

Morrison LH, Morrison S, Moore JM (2020) 18132 Hydroxychloroquine for refractory oral lichen planus. J Am Acad Dermatol 83(6):AB92. https://doi.org/10.1016/j.jaad.2020.06.455CrossRef

39.

Raj SC, Baral D, Garhnayak L, Mahapatra A, Patnaik K, Tabassum S, Dash JK (2021) Hydroxychloroquine-a new treatment option for erosive oral lichen planus. Indian J Dent Res 32(2):192–192. https://doi.org/10.4103/ijdr.ijdr_943_20CrossRefPubMed

40.

Eisen D (1993) Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol 28(4):609–612. https://doi.org/10.1016/0190-9622(93)70082-5CrossRefPubMed

41.

Macario-Barrel A, Balguerie X, Joly P (2003) Traitement du lichen érosif buccal par le thalidomide [Treatment of erosive oral lichen planus with thalidomide]. Ann Dermatol Venereol 130(12 Pt 1):1109–1112 French. https://pubmed.ncbi.nlm.nih.gov/14724512/PubMed

42.

Büyük AY, Kavala M (2000) Oral metronidazole treatment of lichen planus. J Am Acad Dermatol 43(2 Pt 1):260–262. https://doi.org/10.1067/mjd.2000.104683CrossRefPubMed

43.

Verma KK, Mittal R, Manchanda Y (2001) Azathioprine for the treatment of severe erosive oral and generalized lichen planus. Acta Derm Venereol 81(5):378–379. https://doi.org/10.1080/000155501317140197CrossRefPubMed

44.

Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF (2012) Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. Br J Dermatol 167(1):36–43. https://doi.org/10.1111/j.1365-2133.2012.10882.xCrossRefPubMed

45.

Al-Sultany HA, Kawen AA (2020) Effectiveness of oral colchicine in the management of lichen planus. Int J Pharm Res 12(3). https://doi.org/10.31838/ijpr/2020.12.03.057

46.

Shea B, Swinden MV, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P (2013) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 5:CD000951. https://doi.org/10.1002/14651858.CD000951.pub2CrossRef

47.

Husein-ElAhmed H, Gieler U, Steinhoff M (2019) Lichen planus: a comprehensive evidence-based analysis of medical treatment. J Eur Acad Dermatol Venereol 33(10):1847–1862. https://doi.org/10.1111/jdv.15771CrossRefPubMed

48.

Gordon JN, Goggin PM (2003) Thalidomide and its derivatives: emerging from the wilderness. Postgrad Med J 79:127–132. https://doi.org/10.1136/pmj.79.929.127CrossRefPubMedPubMedCentral

49.

Martinez GP, Zabaleta ME, Di Giulio C, Charris JE, Mijares MR (2020) The role of chloroquine and hydroxychloroquine in immune regulation and diseases. Curr Pharm Des 26(35):4467–4485. https://doi.org/10.2174/1381612826666200707132920CrossRefPubMed

50.

Scheinfeld N, Rosenberg JD, Weinberg JM (2004) Levamisole in dermatology: a review. Am J Clin Dermatol 5(2):97–104. https://doi.org/10.2165/00128071-200405020-00004CrossRefPubMed

Title: Systemic non-steroidal immunomodulators for oral lichen planus treatment—a scoping review
Authors: Erick Souza Pedraça
Eduardo Liberato da Silva
Taiane Berguemaier de Lima
Pantelis Varvaki Rados
Fernanda Visioli
Publication date: 03-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Lichen Planus
Methotrexate
Methotrexate
Immunomodulator
Hydroxychloroquine
Published in: Clinical Oral Investigations / Issue 12/2023
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-023-05357-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Systemic non-steroidal immunomodulators for oral lichen planus treatment—a scoping review

Abstract

Objective

Materials and methods

Results

Conclusion

Clinical relevance

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Clinical relevance

Please log in to get access to this content

Other articles of this Issue 12/2023

Inter-observer agreement among specialists in the diagnosis of oral potentially malignant disorders and oral cancer using store-and-forward technology

Influence of antiresorptive/antiangiogenic therapy on changes in periodontal and oral tissue structures: a histomorphometrical analysis in rats

Treatment outcomes of regenerative endodontic procedures in nonvital mature permanent teeth: a retrospective study

A novel method for the remote measurement of trismus in clinical trials using mobile phone cameras

Degradation products of resin-based materials detected in saliva in vivo

Clinical efficacy of endodontic protocols on reducing cultivable bacteria and endotoxin in infected root canal in patients submitted to head and neck radiotherapy: a randomised clinical trial